RAS testing

RAS testing in metastatic colorectal cancer (mCRC)

Signalling through the MAPK pathway leads to an increase in a number of cellular processes relevant to cancer survival, hence the genes and proteins within this pathway are targets for several types of anti-cancer therapy. The epidermal growth factor receptor, EGFR, sits on the cell surface and its activation leads to signalling through the MAPK pathway. Monoclonal antibodies against EGFR inhibit its signalling activity and have proven to be an effective treatment in some cancers.

However, activating mutations in the closely related KRAS and NRAS genes, whose proteins lie downstream of the EGFR molecule in the cell signalling pathway, are found in 30% to 45% of all colorectal tumours. These cause resistance to anti EGFR-antibody therapy in colorectal cancer.

The NewGene Ras mutation test detects specific mutations in exons 2, 3 and 4 of the RAS genes which predict a lack of response to the drugs cetuximab (ErbituxTM) and panitumumab (VectibixTM).

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne
NE1 4EP, UK

Tel: +44 (0)191 242 1923
Fax: +44 (0)191 241 8799
Email: info@newgene.org.uk

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience

Illumina

Sophia Genetics

Qiagen

Promega

Enquiry form